Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Mar;53(3):305-353.
doi: 10.1007/s00535-018-1439-1. Epub 2018 Feb 10.

Evidence-based clinical practice guidelines for inflammatory bowel disease

Katsuyoshi Matsuoka  1 , Taku Kobayashi  1 , Fumiaki Ueno  2   3 , Toshiyuki Matsui  1 , Fumihito Hirai  1 , Nagamu Inoue  1 , Jun Kato  1 , Kenji Kobayashi  1 , Kiyonori Kobayashi  1 , Kazutaka Koganei  1 , Reiko Kunisaki  1 , Satoshi Motoya  1 , Masakazu Nagahori  1 , Hiroshi Nakase  1 , Fumio Omata  1 , Masayuki Saruta  1 , Toshiaki Watanabe  1 , Toshiaki Tanaka  1 , Takanori Kanai  1 , Yoshinori Noguchi  1 , Ken-Ichi Takahashi  1 , Kenji Watanabe  1 , Toshifumi Hibi  1 , Yasuo Suzuki  1 , Mamoru Watanabe  1 , Kentaro Sugano  1 , Tooru Shimosegawa  1
Affiliations
Practice Guideline

Evidence-based clinical practice guidelines for inflammatory bowel disease

Katsuyoshi Matsuoka et al. J Gastroenterol. 2018 Mar.

Abstract

Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn's disease (CD) in Japanese. A total of 59 clinical questions for 9 categories (1. clinical features of IBD; 2. diagnosis; 3. general consideration in treatment; 4. therapeutic interventions for IBD; 5. treatment of UC; 6. treatment of CD; 7. extraintestinal complications; 8. cancer surveillance; 9. IBD in special situation) were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases. The guidelines were developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Recommendations were made using Delphi rounds. This English version was produced and edited based on the existing updated guidelines in Japanese.

Keywords: Consensus; Crohn’s disease; Evidence; Guidelines; Inflammatory bowel disease; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors have received individually any income, honoraria or any other types of remuneration; Abbvie Inc., EA Pharma Co., Ltd., Eisai Co., Ltd., IGAKU-SHOIN Ltd, Yakult Honsha Co., Ltd, Mitsubishi Tanabe Pharma Corporation; and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation); Asahi Kasei Medical Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Abbvie Inc., EA Pharma Co., Ltd., Eisai Co., Ltd., Eidia Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Biofermin Seiyaku Co., Ltd., Pfizer Inc. Bristol-Myers Squibb Company, Merck Serono Co., Ltd. Mochida Pharmaceutical Co., Ltd. Yakult Honsha Co., Ltd., Janssen Pharmaceutical K.K.

Figures

Fig. 1
Fig. 1
Diagnostic approach of UC
Fig. 2
Fig. 2
Diagnostic approach of CD
Fig. 3
Fig. 3
Remission induction treatment for mildly-to-moderately active distal UC
Fig. 4
Fig. 4
Remission induction treatment for mildly-to-moderately active extensive (including left-sided) UC
Fig. 5
Fig. 5
Remission induction treatment for severely active UC
Fig. 6
Fig. 6
Maintenance treatment for UC in remission
Fig. 7
Fig. 7
Remission induction treatment for active CD
Fig. 8
Fig. 8
Treatment for intestinal complications of CD
Fig. 9
Fig. 9
Maintenance treatment for CD in remission
See this image and copyright information in PMC

References

    1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–523. - PubMed
    1. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104(2):465–483. - PubMed
    1. Japan Intractable Diseases Information Center. http://www.nanbyou.or.jp.
    1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124. - PMC - PubMed
    1. Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11(2):154–163. - PubMed

Publication types